Exercise combined with spermidine and rapamycin or lamivudine was feasible in Phase 1b trial
This Phase 1b RCT assessed the safety and feasibility of combining exercise, spermidine supplementation, and either rapamycin or lamivudine in participants. The study evaluated whether this multi-component intervention could be delivered as designed and was tolerated, as a precursor to testing effects on inflammation and aging markers.
What this changes
The finding has not established an approved change to our evidence assessment.
Source date: Aug 27, 2026 · Discovered: Sep 18, 2026 · Assessed: — · Research update
What it does not prove
- Limitations have not yet been verified. Read the primary source.
Extracted from supplied source material; model confidence is not a measured probability of correctness.
Study details
- Design
- Rct
- Sample size
- —
- Duration
- —
- Population
- —
- Primary outcome
- Safety and feasibility of combined exercise, spermidine supplementation, and rapamycin or lamivudine
- Effect size
- —
- Significance
- Not reported
- Journal
- Icahn School of Medicine at Mount Sinai
- Published
- Aug 27, 2026
Sources
Primary source
- Icahn School of Medicine at Mount Sinai ↗Clinical trial
Source versions
Assessment history
9/24/2026 · SUPERSEDED: Source updated; assessment withdrawn pending review.
Discussion (0)
One thread per scientific event, no matter how many outlets covered it.
No comments yet
Be the first to weigh in on this evidence.